The ARL6IP5 Knockout A-549 Polyclonal Cells are a heterogeneous population of A-549 human lung adenocarcinoma cells engineered using CRISPR/Cas9 to disrupt the ARL6IP5 gene. This polyclonal knockout format delivers a robust loss-of-function model that preserves the genetic diversity of the parental line, minimizing clonal artifacts while enabling bulk functional studies of ARL6IP5-dependent pathways.
The A-549 cell line was established from the carcinomatous lung tissue of a 58-year-old male with adenocarcinoma, serving as an adherent epithelial model of alveolar type II pneumocytes. These cells are widely utilized in non-small cell lung cancer research for studying oncogenic signaling, metastatic mechanisms, and therapeutic responses, and they provide a physiologically relevant context for interrogating the tumor-suppressive roles of ARL6IP5.
ARL6IP5 (JWA) is a multifunctional scaffold protein that orchestrates glutamate transporter trafficking by interacting with SLC1A1, and integrin-mediated adhesion via ITGAV and ITGB3, thereby regulating downstream MAPK/ERK and PI3K/AKT cascades. Its expression is induced by transcription factors SP1, AP-1, and HIF1A in response to growth factors (EGF, NGF) and oxidative stress (H2O2). ARL6IP5 forms complexes with glutamate receptor subunits GRIA1 and GRIA2, the motor protein KIF5B, and the scaffold YWHAZ (14-3-3), modulating signaling through MAPK1/ERK2, the anti-apoptotic factor BCL2, and matrix metalloproteinase MMP2. This positions ARL6IP5 at the intersection of adhesive, apoptotic, and redox-sensitive pathways.
Within the A-549 lung adenocarcinoma background, ARL6IP5 ablation is expected to abrogate its tumor-suppressive functions, namely the promotion of oxidative stress-induced apoptosis and inhibition of cell motility. Loss of ARL6IP5 likely enhances invasive potential and alters sensitivity to chemotherapeutic agents by disrupting integrin-PTK2 (FAK) signaling and downstream MAPK1/NFE2L2-dependent oxidative stress responses. This model thus permits dissection of ARL6IP5 contributions to epithelial-mesenchymal transition, anoikis resistance, and glutamate receptor crosstalk in lung cancer.
These polyclonal knockout cells are suitable for a spectrum of assays: MTT and colony formation assess proliferation; transwell migration/invasion chambers evaluate metastatic properties; Annexin V staining detects apoptosis; glutamate uptake and ROS detection assays probe transporter function and redox balance. Western blotting and immunofluorescence confirm modulation of ARL6IP5 targets including SLC1A1, ITGAV, phospho-MAPK1/3, and BCL2. Applications span cancer cell biology, drug resistance screening, oxidative stress research, neurobiology studies of glutamate signaling, and cell adhesion dynamics. For comprehensive technical specifications, contact Ascent Research.
